Research institution
University Hospital Tuebingen Clinical Trials
Studies where University Hospital Tuebingen is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 82Parkinson's Disease
Prevent Cognitive Decline in GBA-associated Parkinson's Disease
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene.
- Trial name
- PreCoDe (NCT07055087)
- Testing
- Prasinezumab, Sodium Chloride
- Where
- 11 sites in France, Germany and 5 more
- Volunteers
- 120 people
- Sponsor
- University Hospital Tuebingen
Cognitive Recovery After Stroke, Cognitive Outcome After Stroke
Long-Term Cognitive Recovery After Arteria Cerebri Media Ischemia: A Digital Assessment Using the TuCAN-App
TuCAN-Media is a longitudinal study investigating cognitive recovery after stroke in severely affected patients (modified Rankin Scale [mRS] score ≥ 3) with large vessel occlusion of the arteria cerebri media/middle cerebral…
- Trial name
- TuCAN-Media (NCT07885189)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Tuebingen
Rectal Cancer
Hyperthermia With Chemoradiotherapy in Rectal Cancer
The goal of this clinical trial is to evaluate the efficacy of deep regional hyperthermia in the context of radiochemotherapy followed by consolidation chemotherapy in locally advanced rectal cancer.
- Trial name
- ARO 2024-13 (NCT06831981)
- Testing
- Hyperthermia, Radiotherapy, Chemotherapy with 5-fluorouracil
- Where
- 2 sites in Germany
- Volunteers
- 264 people
- Sponsor
- University Hospital Tuebingen
Prostate Cancer
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
This trial is a phase II, randomized, open label study designed to evaluate safety, tolerability and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity, and of VACXS15-PC01, a prostate cancer (PC)-specific…
- Trial name
- ImmProCure (NCT07860047)
- Testing
- PSMAxCD3, bispecific antibody CC-1, Multipeptide Vaccine VAC-XS15-PC01
- Where
- 4 sites in Germany
- Volunteers
- 84 people
- Sponsor
- University Hospital Tuebingen
Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2
Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance
The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment ("active surveillance"), in achieving complete healing of a tissue…
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2, CIN2
- Trial name
- CINPLASTA (NCT07730645)
- Testing
- Treatment with low-thermal argon plasma devitalization
- Where
- Germany
- Volunteers
- 264 people
- Sponsor
- University Hospital Tuebingen
Penile Cancer, Penile Neoplasms Malignant
DEfeating PEnile CAncer-2
Open inguinal lymphadenectomy (O-ILAD) is the current standard of care for invasive staging and simultaneously the curative approach for patients with PeCa and elevated risk for or clinically detectable lymphatic disease in the…
- Trial name
- DEPECA-2 (NCT07378670)
- Testing
- open inguinal lymphadenectomy, robot-assisted inguinal lymphadenectomy
- Where
- 9 sites in Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Type2diabetes, PreDiabetes
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
More than 50% of patients with type 2 diabetes develop micro- and/or macrovascular complications during the course of the disease.
- Conditions
- Type2diabetes, PreDiabetes, Renal Failure
- Trial name
- NCT06054035
- Testing
- Dapagliflozin (Forxiga®), Lifestyle Intervention
- Where
- 9 sites in Germany
- Volunteers
- 170 people
- Sponsor
- University Hospital Tuebingen
Fibrolamellar Hepatocellular Carcinoma (FLC)
Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
The aim of this clinical trial is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a DNAJB1-PRKACA fusion transcript-based peptide vaccine (Fusion-VAC-XS15) in patients with FL-HCC or…
- Trial name
- FusionVAC22_02 (NCT06789198)
- Testing
- Vaccination of Fusion-VAC-XS15
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen
Amyloidosis Cardiac, Stenosis Coronary
Non-Interventional Study on the Prevalence of Cardiac Amyloidosis in Patients With Higher-Grade Aortic Valve Stenosis - Evaluation Using Echocardiography, Computed Tomography, Tc99-SPECT/CT and Cardiac Magnetic Resonance Imaging (CMR)
Degenerative aortic stenosis (AS) is frequently accompanied by left ventricular hypertrophy and diastolic dysfunction, features that overlap with transthyretin (ATTR) cardiac amyloidosis.
- Conditions
- Amyloidosis Cardiac, Stenosis Coronary, TAVI(Transcatheter Aortic Valve Implantation)
- Trial name
- NIS-TAVI-AMY (NCT07752732)
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- University Hospital Tuebingen
Alcohol Use During Pregnancy
A Strong Start in Life - ELAS 2.0: A Digital Learning Program to Promote a Healthy Pregnancy and Early Child Protection
The goal of this clinical trial is to evaluate an adapted version of a previously developed e-learning tool to teach sensitive conversations to health professionals working in maternity care.
- Trial name
- ELAS 2 (NCT07782190)
- Testing
- Interprofessional E-Learning Program on Alcohol Use During Pregnancy
- Where
- Germany
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Completed, with results posted
All 5Passive Upper-limb Exoskeleton
Work Physiological-Biomechanical Analysis of a Passive Exoskeleton to Support Occupational Lifting and Flexing Processes
BACKGROUND Industrial tasks that are characterized by high loads, a high repetition rate, and/or awkward body postures, put employees at higher risk to develop work-related musculoskeletal disorders (WRMSD), especially low back…
- Trial name
- ADVANCE (NCT03725982)
- Testing
- Laevo ®, No Laevo ®
- Where
- Germany
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Neuropathic Pain, Phantom Pain
Neuropathic Pain After Orchidectomy and Sex Reassignment Surgery
Phantom pain is associated with cortical reorganization after amputation. This phenomenon should not play a role in transsexual women, since the cortical representation of the male sex organs is presumably altered.
- Conditions
- Neuropathic Pain, Phantom Pain, Sex Reassignment Surgery
- Trial name
- NPASRS (NCT04538170)
- Testing
- pain after surgery
- Where
- Germany
- Volunteers
- 423 people
- Sponsor
- University Hospital Tuebingen
Anesthesia, Caudal
Caudal Block Versus Local Wound Infiltration for Inguinal Procedures
Single-centre observational study to analyse whether there is a difference in post-operative pain scores and set up time when comparing caudal block with local wound infiltration
- Trial name
- NCT04590027
- Volunteers
- 86 people
- Sponsor
- University Hospital Tuebingen
Healthy
Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities
Standing work is associated with increased risks of venous and musculoskeletal disorders; particularly low back pain is commonly reported in prolonged standing work.
- Trial name
- NCT03134144
- Testing
- Exoskeleton "Chairless Chair"
- Where
- Germany
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Recurrent Glioblastoma
Ketogenic Diet for Recurrent Glioblastoma
To determine whether a mild ketogenic diet can influences quality of life and survival of patients with recurrent glioblastoma
- Trial name
- ERGO (NCT00575146)
- Testing
- TAVARLIN
- Where
- 2 sites in Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Tuebingen